The global peripheral vascular devices market, valued at USD 4.7 billion in 2022, is projected to expand at a robust CAGR of 6.6%, reaching USD 8.9 billion by 2032, according to Future Market Insights ...

The lawsuit states that Surmodics, Inc. based in Eden Prairie, is the largest provider in the United States of outsourced ...

Limus-based devices, rather than being a substitute for paclitaxel as they were once seen, are coming of age in peripheral ...

Peripheral vascular devices are critical in the treatment of peripheral vascular ... thereby increasing the number of patients requiring medical interventions and driving market growth. Despite these ...

R3 Vascular Inc., a medical device company dedicated to developing and providing novel, best-in-class bioresorbable scaffolds for treating peripheral arterial disease (PAD), is pleased to announce ...

Analysts have set 12-month price targets for Merit Medical Systems, revealing an average target of $114.12, a high estimate ...

Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the health care industry, today announced the commercial release of the Pounce™ XL ...

R3 Vascular announced that a doctor treated the first patient in the ELITE-BTK pivotal trial of its drug-eluting ...

Analysts expect Penumbra to report an earnings per share (EPS) of $0.67. The announcement from Penumbra is eagerly ...

Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same ...